PURPOSE: The focal adhesion kinase (FAK) is a nonreceptor protein tyrosine kinase important in signaling between cells and their extracellular matrix. Studies have shown that FAK expression is up-regulated in several human tumors and is related to tumor progression. We recently found an increase in p125(FAK) expression in human neuroblastoma cells lines and wished to determine its expression in human neuroblastoma specimens and evaluate for a possible correlation between p125(FAK) expression and known prognostic factors for neuroblastoma. We hypothesized that p125(FAK) expression would be up-regulated in advanced human neuroblastomas. EXPERIMENTAL DESIGN: Using immunohistochemical techniques with monoclonal antibody 4.47 specific for p125(FAK) expression, we analyzed 70 formalin-fixed, paraffin-embedded human neuroblastoma specimens for p125(FAK) staining. In addition, real-time PCR was used to determine the abundance of FAK mRNA in 17 matched human neuroblastoma mRNA specimens. RESULTS: FAK staining was present in 51 of the 70 tumor specimens (73%). Immunohistochemical staining of p125(FAK) in the ganglion-type tumor cells correlated with advanced International Neuroblastoma Staging System tumor stages and FAK mRNA abundance. In addition, p125(FAK) staining was significantly increased in stage IV tumors with amplification of the N-MYC oncogene. CONCLUSIONS: These novel findings provide evidence that FAK is expressed by advanced-stage neuroblastoma and provide a rationale for targeting FAK in the treatment of this tumor.
PURPOSE: The focal adhesion kinase (FAK) is a nonreceptor protein tyrosine kinase important in signaling between cells and their extracellular matrix. Studies have shown that FAK expression is up-regulated in several humantumors and is related to tumor progression. We recently found an increase in p125(FAK) expression in humanneuroblastoma cells lines and wished to determine its expression in humanneuroblastoma specimens and evaluate for a possible correlation between p125(FAK) expression and known prognostic factors for neuroblastoma. We hypothesized that p125(FAK) expression would be up-regulated in advanced humanneuroblastomas. EXPERIMENTAL DESIGN: Using immunohistochemical techniques with monoclonal antibody 4.47 specific for p125(FAK) expression, we analyzed 70 formalin-fixed, paraffin-embedded humanneuroblastoma specimens for p125(FAK) staining. In addition, real-time PCR was used to determine the abundance of FAK mRNA in 17 matched humanneuroblastoma mRNA specimens. RESULTS:FAK staining was present in 51 of the 70 tumor specimens (73%). Immunohistochemical staining of p125(FAK) in the ganglion-type tumor cells correlated with advanced International Neuroblastoma Staging System tumor stages and FAK mRNA abundance. In addition, p125(FAK) staining was significantly increased in stage IV tumors with amplification of the N-MYC oncogene. CONCLUSIONS: These novel findings provide evidence that FAK is expressed by advanced-stage neuroblastoma and provide a rationale for targeting FAK in the treatment of this tumor.
Authors: Lauren A Gillory; Jerry E Stewart; Michael L Megison; Hugh C Nabers; Elizabeth Mroczek-Musulman; Elizabeth A Beierle Journal: Transl Oncol Date: 2013-04-01 Impact factor: 4.243
Authors: Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mrozcek-Musulman; Elizabeth A Beierle Journal: Mol Cancer Res Date: 2014-01-24 Impact factor: 5.852
Authors: Elizabeth A Beierle; Xiaojie Ma; Jerry E Stewart; Michael Megison; William G Cance; Elena V Kurenova Journal: Mol Carcinog Date: 2012-10-12 Impact factor: 4.784
Authors: Elizabeth A Beierle; Xiaojie Ma; Angelica Trujillo; Elena V Kurenova; William G Cance; Vita M Golubovskaya Journal: Mol Carcinog Date: 2010-03 Impact factor: 4.784
Authors: Michael L Megison; Jerry E Stewart; Hugh C Nabers; Lauren A Gillory; Elizabeth A Beierle Journal: Clin Exp Metastasis Date: 2012-12-04 Impact factor: 5.150
Authors: Jerry E Stewart; Xiaojie Ma; Michael Megison; Hugh Nabers; William G Cance; Elena V Kurenova; Elizabeth A Beierle Journal: Mol Carcinog Date: 2013-07-19 Impact factor: 4.784